(R)-1-(4-(methylsulfonyl)phenyl)ethan-1-ol | 726192-01-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-1-(4-(methylsulfonyl)phenyl)ethan-1-ol
• 英文别名: (R)-1-(4-methylsulfonylphenyl)ethanol；(1R)-1-(4-methanesulfonylphenyl)ethan-1-ol；(1R)-1-(4-methylsulfonylphenyl)ethanol
• CAS: 726192-01-4
• 化学式: C₉H₁₂O₃S
• mdl: MFCD09863784
• 分子量: 200.258
• InChiKey: NYXCSMWVRWOPJP-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-1-(4-(methylsulfonyl)phenyl)ethan-1-ol 在 titanium(IV) isopropylate 、 胸苷酸 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 生成 4-{(S)-4-[(S)-1-(4-Methanesulfonyl-phenyl)-ethyl]-3-methyl-piperazin-1-yl}-4-methyl-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. II. Discovery of 1-[(2,4-Dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoro- methyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-Oxide (Sch-350634), an Orally Bioavailable, Potent CCR5 Antagonist

  摘要：

  Truncation of the original piperidino-2(S)-methyl piperazine lead structure 2, from a family of muscarinic antagonists, gave compound 8 which has improved selectivity for the HIV-1 co-receptor CCR5 over muscarinic receptors. Further optimization for pharmacokinetic properties afforded Sch-350634 (1), a prototypical piperazine-based CCR5 antagonist, which is a potent inhibitor of HIV-1 entry and replication in PBMCs. The title compound (1) has excellent oral bioavailability in rat, dog, and monkey.

  DOI：

  10.1021/jm0155401
• 作为产物：
  描述：

  4-甲砜基苯乙酮 在 C₃₇H₄₀MnN₂O₂P₂⁽¹⁺⁾*Br^(1-) 、 sodium t-butanolate 作用下， 以 异丙醇 为溶剂， 反应 3.0h， 以93%的产率得到(R)-1-(4-(methylsulfonyl)phenyl)ethan-1-ol
  参考文献：
  名称：

  锰（I）催化的酮的不对称转移加氢：揭示大环特权。

  摘要：

  具有手性（NH）2 P2大环配体（1）的双（羰基）锰（I）配合物[Mn（CO）2（1）] Br（2）催化2-丙醇对极性双键的不对称转移加氢反应作为氢源 酮（43种底物）以高收率（高达> 99％）和出色的对映选择性（90-99％ee）被还原为醇。提出了基于有吸引力的CH-π相互作用的立体化学模型。

  DOI：

  10.1002/anie.201912605

文献信息

• Piperazine derivatives useful as CCR5 antagonists
  申请人：Schering Corporation

  公开号：US06391865B1

  公开（公告）日：2002-05-21

  The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  公开了使用CCR5拮抗剂的公式，其中 R是可选择的取代苯基，吡啶基，噻吩基或萘基; R1是氢或烷基; R2是取代苯基，取代杂环基，萘基，芴基，二苯甲基或可选择的取代苯基或杂环基烷基; R3是氢，烷基，烷氧基烷基，环烷基，环烷基烷基，或可选择的取代苯基，苯基烷基，萘基，萘基烷基，杂环基或杂环基烷基; R4，R5和R7是氢或烷基; R6是氢，烷基或烯基; 用于治疗HIV，固体器官移植排斥，移植物宿主病，关节炎，类风湿关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化症的方法，以及包含它们的新化合物，包含它们的药物组合物，以及CCR5拮抗剂与抗HIV治疗中有用的抗病毒剂或与治疗炎症性疾病中有用的药物的组合。
• NOVEL TRICYCLIC CHIRAL COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYSIS
  申请人：Loh Teck Peng

  公开号：US20110269972A1

  公开（公告）日：2011-11-03

  The present invention relates to a compound of general Formula (XX), its formation and its use in asymmetric catalysis. In Formula (XX) R and R 31 are independently —COOR 3 , —R 4 COOR 3 , —R 4 CHO, —R 4 COR 3 , —R 4 CONR 5 R 6 , —R 4 COX, —R 4 OP(═O)(OH) 2 , —R 4 P(═O)(OH) 2 ), —R 4 C(O)C(R 3 )CR 5 R 6 and —R 4 CO 2 COR 3 . In addition, R 31 may also be hydrogen. R 3 , R 5 and R 6 are independently hydrogen, an aliphatic group with a main chain having 1 to about 20 carbon atoms, an alicyclic group, an aromatic group, an arylaliphatic group or an arylalicyclic group, comprising 0 to about 3 heteroatoms independently selected from the group consisting of N, O, S, Se and Si. R 4 an aliphatic bridge with a main chain having 1 to about 20 carbon atoms, an alicyclic bridge, an aromatic bridge, an arylaliphatic bridge or an arylalicyclic bridge, comprising 0 to about 3 heteroatoms independently selected from the group consisting of N, O, S, Se and Si, and X is halogen. In Formula (XX) R 30 is —C(OH)R 1 R 2 or —COOR 14 , wherein R 1 , R 2 and R 14 are independently hydrogen, an aliphatic group with a main chain having 1 to about 20 carbon atoms, an alicyclic group, an aromatic group, an arylaliphatic group or an arylalicyclic group, comprising 0 to about 3 heteroatoms independently selected from the group consisting of N, O, S, Se and Si.

  本发明涉及一种一般式（XX）的化合物，其形成以及在不对称催化中的应用。在式（XX）中，R和R31独立地为—COOR3，—R4COOR3，—R4CHO，—R4COR3，—R4CONR5R6，—R4COX，—R4OP(═O)(OH)2，—R4P(═O)(OH)2，—R4C(O)C(R3)CR5R6和—R4CO2COR3。此外，R31也可以是氢。R3、R5和R6独立地为氢，具有主链含有1至约20个碳原子的脂肪基团，脂环基团，芳香基团，芳基脂基团或芳基脂环基团，包括0至约3个从N、O、S、Se和Si组成的杂原子。R4为具有主链含有1至约20个碳原子的脂肪桥，脂环桥，芳香桥，芳基脂桥或芳基脂环桥，包括0至约3个从N、O、S、Se和Si组成的杂原子，X为卤素。在式（XX）中，R30为—C(OH)R1R2或—COOR14，其中R1、R2和R14独立地为氢，具有主链含有1至约20个碳原子的脂肪基团，脂环基团，芳香基团，芳基脂基团或芳基脂环基团，包括0至约3个从N、O、S、Se和Si组成的杂原子。
• Alternative Hydrogen Source for Asymmetric Transfer Hydrogenation in the Reduction of Ketones
  作者：Russell J. Wakeham、James A. Morris、Jonathan M. J. Williams

  DOI：10.1002/cctc.201500886

  日期：2015.12

  cis‐1,4‐Butenediol is shown to be a highly active hydrogen source for asymmetric transfer hydrogenation in the reduction of ketones. With the use of a ruthenium catalyst, cis‐1,4‐butenediol is isomerised and subsequently oxidised to a lactone as an irreversible step, which provides the driving force for the asymmetric reduction of ketones.

  顺式-1,4-丁二醇是一种高活性氢源，可用于酮还原中的不对称转移氢化。通过使用钌催化剂，顺式-1,4-丁二醇被异构化，随后被氧化为内酯，这是不可逆的步骤，这为酮的不对称还原提供了驱动力。
• Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives
  申请人：Nitz Theodore J.

  公开号：US20090215778A1

  公开（公告）日：2009-08-27

  Derivatives of pyrazolopyrimidine compounds represented by Formula I are disclosed: These pyrazolopyrimidine derivatives and pharmaceutical compositions comprising these derivatives are useful in the treatment of HIV mediated diseases and conditions.

  公开了由式I表示的吡唑吡咯啉衍生物的衍生物：这些吡唑吡咯啉衍生物和包含这些衍生物的制药组合物在治疗艾滋病毒介导的疾病和病况方面是有用的。
• Potent and highly selective DP1 antagonists with 2,3,4,9-tetrahydro-1H-carbazole as pharmacophore
  作者：Lianhai Li、Christian Beaulieu、Marie-Claude Carriere、Danielle Denis、Gillian Greig、Daniel Guay、Gary O’Neill、Robert Zamboni、Zhaoyin Wang

  DOI：10.1016/j.bmcl.2010.10.018

  日期：2010.12

  We discovered that the introduction of a methyl group to the benzylic position of the N-benzyl group in lead compound 1a has a dramatic effect on improving the binding selectivity of this ligand for the prostanoid receptors DP1 (receptor for prostaglandin D(2)) as compared to TP (receptor for thromboxane A(2)). Based on this discovery, we have synthesized a series of potent and highly selective DP1 antagonists. Among them, compound 1h was identified as a highly selective DP1 antagonist with excellent overall properties. It has a K(i) of 0.43 nM to DP1 in binding assay and an IC(50) of 2.5 nM in the DP1 functional assay. Its selectivity for DP1 over TP (the most potent receptor after DP1) exceeds 750-fold based on both binding and functional assays. These properties make 1h a very potent and highly selective DP1 receptor antagonist suitable for investigating the biological functions of DP1 in normal physiology and models of disease (C) 2010 Elsevier Ltd. All rights reserved.